The antibody drug conjugates contract market size is estimated to be USD 9,867.1 million in 2022 and is expected to witness a CAGR of 12.99% during the forecast period 2023-2033. The complexity of ADCs and rising demand for manufacturing capacity are projected to drive the market growth in near future. Furthermore, increase in research on antibody therapeutics and surge in collaborations to increase the demand for ADC CMO activities are other factors supporting the market growth. However, high price of medicine development and distribution and a shortage of skilled workers are predicted to limit market growth.

Increase in research on antibody therapeutics is expected to spur the market growth during the projected period. Scientists have improved the design and development process for these medications over time and through research. Four new ADCs will therefore be approved between 2019 and 2020. There are now 100 ADCs awaiting approval by the US Food and Drug Administration.

Surge in collaborations to increase the demand for ADC CMO activities is predicted to fuel the market growth during the forecast period. In order to give their customers high-quality ADCs, ADC CMOs also invest to enhance their bioconjugation and manufacturing capabilities. For instance, the biotechnology company Singzyme and CMO Lonza partnered in October 2022. According to the collaboration, Lonza may produce ADC more rapidly by using Singzyme’s enzymatic conjugation platform. These partnerships would increase the demand for ADC CMO activities and thus help the sector expand. Over 14 ADCs had received worldwide commercial approval as of 2021, according to the European Pharmaceutical Review (EPR). Over 140 ADCs are currently being developed, according to the EPR.

Segmentation

By Condition

The market is categorized into breast cancer, myeloma, lymphoma and others (urothelial cancer). In 2022, the myeloma segment accounted for the highest revenue share due to the fact that they have a great potential for usage in the treatment of myeloma. A new type of medication called ADCs for myeloma targets only the myeloma cell with a potent cytotoxic chemical. Bystander cell damage is decreased and a therapeutic window is made accessible by this method of action. It can be used for a wide range of patients and in practically all myeloma treatment clinics. These factors are boosting ADC’s demand for myeloma therapy and driving the segment’s expansion. The lymphoma segment is anticipated to have the fastest CAGR over the forecast period. Many people around the world are affected by lymphoma. According to Cancer Tomorrow, there will be 83,100 new cases of Hodgkin lymphoma worldwide in 2020, compared to more than 544,000 new cases of non-Hodgkin lymphoma. There are three ADC treatments for lymphoma that are currently approved: Adcetris, Polivy, and Zynlonta. The majority of the commercially available ADCs are employed in the management of lymphoma and breast cancer.

By Linker

The market is segmented into non-cleavable linker and cleavable linker. In the global market, the cleavable linker segment accounted for the largest revenue share in 2022 owing to advantages that cleavable linkers provide in some situations to deliver the medication to the target cell. The success of an ADC is believed to be largely dependent on the properties of the linker that connects the antibody and the payload. The efficiency of cleavable linkers is due to their ability to effectively differentiate between circulatory and target-cell conditions. The non-cleavable linker segment is anticipated to register the fastest CAGR over the projected period. ADCs made with a non-cleavable linker depend on the lysosomal breakdown of the ADC, which releases the cytotoxic chemicals once the ADC molecule has been internalized in the target cell. The total cytotoxicity of the ADC to neighbouring healthy cells is decreased as a result of limiting the drug’s non-specific release. Non-cleavable linkers also have a longer half-life in circulation and higher plasma stability than cleavable linkers, both of which can increase the therapeutic window. The segment growth is being aided by the factors listed above.

Regional Markets

In 2022, Asia Pacific region accounted for the highest revenue in the antibody drug conjugates contract market and is expected to maintain its dominance during the forecast period. This is attributed to prevalence of cancer. 9.4 million cases of cancer were reported in Asia in 2020, and Cancer Tomorrow predicts that this figure would increase to 14.2 million by 2040. Thus, an increase in cancer cases is anticipated to enhance the market for ADC’s manufacturing by increasing the demand for targeted medicines like it. In addition, compared to industrialized economies, contract manufacturing costs are relatively low in the Asia-Pacific region. Additionally, North America contributed significantly to sales in 2022. This expansion can be attributed to the increase in biopharmaceutical companies in the United States and Canada. The expansion of important players in this region is anticipated to have a impact on the growth of the area. Additionally, the regional regulatory authority actively grants ADCs regulatory approval. For instance, as of 2021, the USFDA had approved 12 ADCs. This increases its commercial viability and encourages the region’s acceptance of it.

Competitor Insights

Some of the key players operating in the antibody drug conjugates contract market are Sartorius AG, Lonza, Samsung BioLogics, Recipharm AB, Piramal Group (Piramal Pharma Solutions), Abbvie, Inc. (Abbvie Contract Manufacturing), Catalent, Inc., Wuxi Biologics, Sterling, and Merck KGaA.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Sterling invested USD 1.3 million in April 2022 to expand its U.K. site, which is focused to enhancing cGMP bioconjugation/ADC production capabilities.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including condition and linker from 2022 to 2033.

Report Scope:

Segmentation: Antibody Drug Conjugates Contract Market Report 2022 – 2033

Condition (Revenue, USD Million), 2022 – 2033

• Breast Cancer
• Myeloma
• Lymphoma
• Others (Urothelial Cancer)

Linker (Revenue, USD Million), 2022 – 2033

• Non-cleavable Linker
• Cleavable Linker

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA